OV-Cmab-CCL5(OV-Cmab-CCL5) - 药物靶点：CCR1 x EGFR_在研适应症：胶质母细胞瘤_专利_临床

概要

基本信息

药物类型

溶瘤病毒

别名-

靶点

CCR1 x EGFR

作用机制

CCR1调节剂(C-C趋化因子受体1型调节剂)、EGFR拮抗剂(表皮生长因子受体erbB1拮抗剂)

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症

胶质母细胞瘤

非在研适应症-

原研机构

City of Hope National Medical Center

在研机构

City of Hope National Medical Center

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 OV-Cmab-CCL5 相关的临床结果

登录后查看更多信息

100 项与 OV-Cmab-CCL5 相关的转化医学

登录后查看更多信息

100 项与 OV-Cmab-CCL5 相关的专利（医药）

登录后查看更多信息

2

项与 OV-Cmab-CCL5 相关的文献（医药）

2023-01-09·Cancer Discovery

A Cetuximab–CCL5 Fusion Protein–Expressing Oncolytic Virus Has Efficacy in GBM

Article

AbstractThe oncolytic virus OV-Cmab-CCL5 induces immune cell infiltration and tumor reduction in glioblastoma.

Nature Cancer

Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity

Article

作者: Hu, Weidong ; Caligiuri, Michael A ; Ma, Rui ; Tian, Lei ; Kaur, Balveen ; Yu, Jianhua ; Chen, Yuqing ; Xu, Bo ; Chiocca, E Antonio ; Cao, Shuai ; Zhang, Jianying ; Wang, Jing ; Li, Zhenlong

Chemokines such as C-C motif ligand 5 (CCL5) regulate immune cell trafficking in the tumor microenvironment (TME) and govern tumor development, making them promising targets for cancer therapy. However, short half-lives and toxic off-target effects limit their application. Oncolytic viruses (OVs) have become attractive therapeutic agents. Here, we generate an oncolytic herpes simplex virus type 1 (oHSV) expressing a secretable single-chain variable fragment of the epidermal growth factor receptor (EGFR) antibody cetuximab linked to CCL5 by an Fc knob-into-hole strategy that produces heterodimers (OV-Cmab-CCL5). OV-Cmab-CCL5 permits continuous production of CCL5 in the TME, as it is redirected to EGFR⁺ glioblastoma (GBM) tumor cells. OV-Cmab-CCL5 infection of GBM significantly enhances the migration and activation of natural killer cells, macrophages and T cells; inhibits tumor EGFR signaling; reduces tumor size; and prolongs survival of GBM-bearing mice. Collectively, our data demonstrate that OV-Cmab-CCL5 offers a promising approach to improve OV therapy for solid tumors.

100 项与 OV-Cmab-CCL5 相关的药物交易

登录后查看更多信息